TGTXTG Therapeutics, Inc.

$54.13+55% 1Y

Is it safe?

Watch

One accounting flag to check: a safe balance sheet, but an accounting pattern worth a look (common in fast growers) and big price swings.

1 good, 2 to watch, 3 neutral
SurvivalSafe zone

Financially healthy, low distress risk Altman Z-score, a bankruptcy-risk model from five balance-sheet ratios.

Honest booksElevated risk

Several accounting flags in the manipulation-likely range Beneish M-score, a forensic model that detects earnings-manipulation patterns (receivables outrunning sales, margins slipping, accrual-heavy profit).

Quality4 / 9

Mixed fundamental signals Piotroski F-score, nine pass/fail tests of year-over-year financial health across profitability, balance sheet and efficiency. 7 to 9 is strong, 0 to 3 weak.

Insider conviction-$275K

Insiders were net sellers (-$275K, 90 days to Oct 22, 2026), selling is often routine.

Credit gradeBBBderived · Jun 30, 2026

Investment-grade balance sheet. A rule of thumb on leverage, not a credit rating.

Drawdown risk53% volderived · Oct 23, 2026

Large price swings, high volatility. Worst drawdown -93% · now 8% below its 52-week high.

Unless marked, from SEC EDGAR, as of Dec 31, 2025.

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

Volatilitybehind 70% of the market
Max drawdownbottom 8% of the market

Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.

Can TGTX take a bad year?

TG Therapeutics, Inc. carries $193M of net debt at 1.42× EBITDA: a load its earnings can carry.

$193M

Net debt · as at Q2 2026 · under two and a half years of EBITDA, comfortable

Net debt / EBITDA
1.42×

Net debt / EBITDA · −0.08× a year ago · the load is going up

Altman Z-score
12.05

Altman Z-score · safe zone, above 3

Interest cover
3.64×

Interest cover · operating profit covers the interest bill, with room to spare

Details›
Total debtQ2 2026
$745M
Cash and short-term investments
$552M
Net debt
$193M
EBITDA, trailing twelve months
$136M
Operating profit, trailing twelve months
$136M
Debt / equity
1.23×
Total debt / EBITDA
5.46×
Annualised volatilitytwo years of daily moves
53%
Worst drawdown on file
−93%
Below its 52-week high
8.3%

Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.

The balance sheet

What it owes against what it owns, and how close that comes to trouble.

How far can it fall?

How much the price moves, how deep and how long its falls have run, and what each unit of risk has paid.